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Abstract
Introduction As part of its mission, the US Food and
Drug Administration (FDA) communicates with the public
regularly about the benefits and risks of prescription and
over-the-counter (OTC) drugs. Effectively communicating
risk, however, is a significant public health challenge.
Objective To better understand how different populations
understand information communicated by the FDA about
drug safety, we conducted a randomized experiment to
examine comprehension and other measures of effective-
ness of drug safety messages that occurred in a post-market
surveillance phase.
Methods We used an Internet panel survey of 1244 con-
sumers, of whom 58 % used prescription drugs in the past
year. Half of the sample panel was randomized to read a
previous FDA Drug Safety Communication (DSC) with the
drug name changed, and the other halfwas randomized to read
a revised version of the sameDSC.We examined howmaking
certain modifications to the way drug risk information is
communicated has an impact on comprehension and behav-
ioral intentions, including the user’s likelihood of discontin-
uing the drug. We also studied how comprehension varied by
respondent characteristics, health literacy skills, risk percep-
tions, and trust in the message.
Results Based on a five-item comprehension index, the
revised version of the message was associated with signifi-
cantly greater comprehension of the information relative to the
standard version (63 vs 52 %correct, p\0.001). Significantly
more respondents found the revised version to be clear (82 vs
73 %, p\0.000), while fewer in that group reported learning
something new (78 % vs 84 %, p = 0.015). No significant
differences emerged between the two groups in terms of the
message being informative, convincing, or helpful. We found
no significant differences between the two groups in terms of
behavioral intentions, risk perception, and trust.
Conclusions We found that making plain language chan-
ges to the DSC significantly increased consumers’ level of
comprehension of its content, providing support for ongoing
use and further exploration of these strategies in pharma-
covigilance communication research. The study findings
have important implications for future drug safety and other
communication messages related to prescription drugs.
Key Points
More use of plain language, and clear
communication changes to drug safety
communications may increase consumers’ level of
comprehension of the content.
Consumers’ health literacy levels were a key factor
in respondents’ level of understanding of the drug
safety communication.
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1 Introduction
Risk communication has been described as ‘‘one of the
greatest challenges facing any public health agency’’ [1].
Risk communication has been used to communicate about
risks related to public health topics such as periodic out-
breaks of food-borne illnesses, the dangers of using
tobacco products, and environmental degradation [2–4].
The process of communicating risk involves altering indi-
viduals’ perceived risk of negative consequences (or their
mental models of risk) associated with adopting new
behaviors, reducing risky behaviors, and increasing
screening and treatment-seeking behaviors [5–9].
Risk communication is a core strategic function of the
US Food and Drug Administration (FDA). The FDA’s
mission is to promote, protect, and advance public health;
in part, by assuring the safety, efficacy, and security of
human drugs. The FDA serves the public interest best when
consumers and healthcare professionals (HCPs) have
timely and understandable information on the benefits and
risks of marketed drugs needed to arrive at optimal treat-
ment decisions [10]. The FDA focuses on communicating
frequently and clearly about benefits and risks to help guide
citizens in making choices about prescription and over-the-
counter drugs, foods, medical devices, cosmetics, tobacco,
and other products.
The public needs appropriate and timely communica-
tions about prescription drugs and the benefits and risks
associated with their use, including risks that arise after
the drugs are on the market and being prescribed. About
49 % of Americans have used at least one prescription
drug in the past month, 31 % have used two or more
drugs, and more than 76 % of people 60 years or older
have used two or more drugs [11, 12]. To help ensure
continued safe and effective use after the FDA approves
a drug, the Agency continues to evaluate its benefits and
risks. Much information is communicated about a drug
throughout the product’s lifecycle. Some of these com-
munication activities include prescribing information,
product labeling, and package inserts; drug advertising
and product claims; warning letters to manufacturers that
violate laws governing advertising and product claims;
adverse event reports made by consumers and HCPs; and
postmarket Drug Safety Communications (DSCs) from
the FDA.
A primary risk communication tool is the FDA DSCs,
which provide emerging postmarket safety information
about approved drugs, or ‘public pharmacovigilance com-
munications’ [13]. DSCs are electronic communications in
a standardized format that are posted in English and
Spanish on the FDA’s website. DSCs are targeted to the
general public, patients, and HCPs. Typically, they
summarize the nature of the safety risk being addressed;
present facts, including established indications and benefits
of the drug; recommend actions for patients and HCPs; and
summarize new data that the FDA has reviewed or is in the
process of investigating. They are disseminated through
multiple channels, including MedWatch Safety Alerts,
targeted stakeholder e-mails and calls, FDA updates for
Health Professionals and Drug Information listservs, FDA
social media accounts, drug safety podcasts, and through
other outlets. Some sources of information that feed into
the DSCs include clinical trials and observational studies,
systematic reviews, pooled analyses and meta-analyses,
and spontaneous reports [14].
A systematic review of 49 published studies found that
although some FDA drug risk communications (including
advisory and label changes) had immediate and strong
impact, many had either delayed or no impact on health-
care utilization or health behaviors [15]. Advisories rec-
ommending greater monitoring did not appear to lead to
large and sustained changes in patient or prescriber
behavior; and in some cases, the speed of adopting warning
information varied depending on whether it was for new or
continuing medication users [15]. In addition, the potential
for unintended consequences from drug risk communica-
tions is an ongoing concern, with notable public health
implications from messaging related to certain medica-
tions, such as birth control pills [16].
Several factors may impact the effectiveness of risk
communications related to emerging drug safety issues. For
example, a substantial proportion of Americans have low
health literacy [17, 18], and people with low numeracy
often err in their understanding of the benefits and risks of
treatment, typically overestimating the benefits of treat-
ment [19]. Certain strategies can facilitate more effective
communication of risk information, including presenting
information using absolute (versus relative) risk (or pro-
viding both), using frequencies (versus percentages), pay-
ing careful attention to time frames associated with the data
(e.g., 10 years), and supporting data with visual cues such
as graphics [19].
The primary objective of the present research is to
understand how adults in the US differ with respect to their
comprehension of, as well as their need and preferences
for, emerging safety information about prescription drugs.
We examine the types of information about prescription
drugs consumers prefer and report using, and to what
extent they are able to understand benefit and risk infor-
mation in general, as well as in the context of a specific
sample communication they received. The outcomes of
exposure to the sample drug safety message we assessed
include the extent to which consumers are likely to talk
with their healthcare professional, report symptoms, and
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discontinue taking the medication. Using a randomized
design, we also tested how making modifications in the
way risk information about a drug is communicated using
clear communication and health literacy principles can
have an impact on comprehension, risk perceptions,
behavioral intentions, message receptivity, and trust.
2 Data and Methods
2.1 Study Design
The study used an Internet panel survey to collect
measures of consumer perceptions about emerging drug
safety information and the effects of modifying a sample
DSC on a specific drug safety issue. Half of the study
sample was randomized electronically to receive a pre-
viously developed drug safety message about a fictitious
drug used for smoking cessation; the other half of the
sample was exposed to a revised version of the same
message (see electronic supplementary material 1 for
additional information about the sample allocation pro-
cess). Study investigators were blinded to the random-
ization process. Inclusion criteria included ensuring that
at least half of participants or a family member used a
prescription drug in the past year and that at least one-
third of the participants had no more than a high-school
education. These and other sociodemographic character-
istics were also considered in developing the weight
variable. Sample size was determined based on power
calculations for the primary outcomes with at least a
90 % power for detecting small effects (Cohen’s
d = 0.2). Human subjects approval was obtained for this
research. No changes were made to the study design
after the study commenced.
2.2 Intervention
For the previous version of the drug safety message
(‘Standard version’), we used a DSC released online in a
single-page, long-form format before FDA instituted the
multi-tabbed DSC format, with more plain language and
other general content modifications. When creating the
revised version, the drug name was changed to ‘Smoquit,’
a fictitious name. For the revised version of the drug safety
message (‘Revised version’), we applied plain language
[20], clear communication [21], and health literacy prin-
ciples to test whether the changes would improve read-
ability and uptake of the information, or influence other
measures. The reading level of the Standard version was
grade 11 and for the Revised version it was grade 8, using
the Simple Measure of Gobbledygook (SMOG) test [22].
Table 1 presents a side-by-side comparison of various
elements of the Standard and Revised versions of the
message.
Briefly, the Revised version retained the same general
content as the Standard version but used the active voice,
made behavioral recommendations more action oriented,
used less complex language, ‘chunked’ information with
additional subheadings, and provided both quantitative and
qualitative data with appropriate context and explanation.
For example, the text describing a meta-analysis was
revised to use simpler terminology and given a plain lan-
guage subheading called ‘Looking at the best evidence.’
Language used in the Standard version was reworded in the
Revised version and was also added to the main safety
announcement to explain to patients the likelihood of
experiencing an adverse event when taking the medication.
The Standard version reported these numbers only in the
data summary section aimed at healthcare professionals,
stating that ‘‘there was a low incidence of major cardio-
vascular events occurring within 30 days of treatment
discontinuation (Smoquit 0.31 % [13/4190]).’’ The
Revised version was reworded to state ‘‘the chance of
someone having a heart-related problem if they took
Smoquit was 31 in 10,000 (0.31 %).’’
2.3 Data Collection and Panel Survey
Data were collected using a KnowledgePanel [23] prob-
ability-based Internet sample that is designed to be repre-
sentative of US households. GfK, the developer of
KnowledgePanel, uses address-based sampling of a com-
puterized file updated every 2 months that contains all
delivery point addresses serviced by the US Postal Service
(over 125 million records with 97 % coverage of US
households). This approach reduces sampling biases that
are introduced through the use of random digit dialing and
Internet-based sampling methods because it includes non-
telephone and non-Internet households.
Individuals who agree to be on the panel can use their
own computers connected to the Internet to take surveys;
netbooks and Internet access are provided to panel mem-
bers living in non-Internet households. Panel ‘case man-
agers’ provide telephone support to households that require
help connecting their computers to the Internet, accessing
their e-mail, and accessing and responding to Internet
surveys. KnowledgePanel consists of about 50,000 US
residents aged 18 or older, and includes people living in
cell-phone-only households. Numerous internal and inde-
pendent assessments of the representativeness of Knowl-
edgePanel samples have been conducted; no evidence of
selection bias or bias attributable to time in the panel were
identified [24].
The survey was fielded between July 24 and August 20,
2013.
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Table 1 Side-by-side comparison of Standard version and Revised version of 2012 FDA Drug Safety Communication (DSC)
Standard version of the DSC Revised version of the DSC
Title: FDA Drug Safety Communication: Safety review update of
Smoquit and risk of cardiovascular adverse events
Title: Talk with your health care professional if you are taking Smoquit
and have new or worsening symptoms of heart or blood-vessel
disease
What is Smoquit? What is Smoquit?
A prescription drug used to help adults quit smoking that works by
blocking the effects of nicotine from smoking on the brain.
It increases the likelihood of abstinence from smoking for as long as
one year compared to treatment with a placebo
Smoquit is a non-nicotine prescription medicine that—along with quit
smoking materials and/or programs—helps people 18 and older stop
smoking
Looking at the best evidence
The U.S. Food and Drug Administration (FDA) is informing the public
about the results of a large, combined analysis, also called a meta-
analysis, of clinical trials that compared patients who received the
smoking cessation drug Smoquit to patients who received a placebo,
which is a treatment with no drug in it
The Food & Drug Administration (FDA) asked the drug company that
makes Smoquit to review all of the large and well done studies of
Smoquit
FDA required the manufacturer of Smoquit to conduct the meta-
analysis to further evaluate the cardiovascular safety of the drug, and
believes it is important to let health care professionals and patients
know about the results of this study
FDA wanted to better understand the effect Smoquit has on heart and
blood-vessel health, also called cardiovascular health
FDA first notified the public about a possible increased risk of
cardiovascular adverse events with Smoquit in its June 2011 Drug
Safety Communication (DSC)
All of the studies compared people who were taking Smoquit to people
who were taking a sugar pill that contains no drug, also known as a
placebo
What did they find?
A higher occurrence of major adverse cardiovascular events was
observed in patients using Smoquit compared to placebo. Major
adverse cardiovascular events were defined as a combined outcome
of cardiovascular-related death, nonfatal heart attack, and nonfatal
stroke
Looking at the combined results of all the studies, people taking
Smoquit were more likely than people taking placebos to have had
one or more of the following heart-related problems:
• death related to cardiovascular problems;
• non-deadly heart attacks; and
• non-deadly stroke
These events were uncommon in both the Smoquit and placebo groups,
and the increased risk was not statistically significant, which means it
is uncertain whether the excess risk for the Smoquit group was due to
the drug or due to chance
The chance of having a heart-related problem was rare in both groups.
The chance of someone having a heart-related problem if they took
Smoquit was 31 in 10,000 (0.31 %). A person taking a placebo had a
21 in 10,000 chance (0.21 %) of having a heart-related problem. This
difference in having heart-related problems could be due to chance
However, the data were analyzed many different ways and consistently
showed a higher occurrence of events in patients using Smoquit,
which makes it seem more likely that it is related to the drug and not
purely a chance finding
But FDA suspects that these heart problems may be due to Smoquit.
FDA believes this because people taking Smoquit were consistently
more likely to have these heart problems than people taking placebos
The meta-analysis findings of cardiovascular risk are similar to the
findings in the smoking cessation clinical trial of patients with
stable cardiovascular disease that was described in FDA’s June 16,
2011 DSC. The Warnings and Precautions section of the Smoquit
label has been updated to include the results of the meta-analysis
The makers of Smoquit have updated theWarnings and Precautions on
the medicine’s label to include this new information
How does this affect me?
Patients taking Smoquit should contact their health care professional if
they experience new or worsening symptoms of cardiovascular
disease, such as chest pain; shortness of breath; calf pain when
walking; or sudden onset of weakness, numbness, or difficulty
speaking
Patients: The health benefits of quitting smoking are immediate and
substantial. Talk to your health care professional if you are taking
Smoquit and have any new symptoms of heart and blood-vessel
disease, or if your condition seems to be getting worse. These
symptoms include:
• chest pain;
• shortness of breath;
• calf pain when walking; or
• suddenly feeling weak, numb, or having difficulty speaking
Report any side effects you experience to your health care professional
and the FDA MedWatch program. Patients should also contact their
health care professional if they have any questions or concerns about
Smoquit
Report any side effects that you have to your health care professional
and the FDA MedWatch program. You should also contact your
health care professional if you have any questions or worries about
Smoquit
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2.4 Measures
The comprehension and behavioral intention questions
were specifically developed to align with the intervention
for this study. The health literacy items are from a vali-
dated scale. All measures were prespecified and were not
changed once data collection commenced.
2.4.1 Dependent Variables
Comprehension We measured respondents’ comprehension
of the Smoquit DSC using five survey items (a = 0.70)
developed specifically for this study and based on the
content included in the DSC. The questions examined
respondents’ awareness and knowledge about the follow-
ing: (1) How common are major cardiovascular or heart-
related events? (2) Who is most likely to have heart-related
problems? (3) When should patients taking Smoquit con-
tact their healthcare professional? (4) What is the likeli-
hood of experiencing an adverse event? and (5) What are
FDA’s recommendations for patients taking Smoquit?
Each survey item had a single correct answer; conse-
quently, we created a five-item ‘comprehension index’
reflecting the proportion of correct answers to these ques-
tions. Respondents were told at the end of the survey that
the message was about a fictitious drug.
Message Assessment, Risk Perception, and Trust of the
Source Respondents were asked five questions about the
utility of the DSC; specifically, whether it was (1) clear, (2)
informative, (3) convincing, (4) helpful, and (5) did they
learn something new. These questions used a 1–4 response
scale, with 1 = Strongly disagree and 4 = Strongly agree.
We summed the responses to these items to create a 5-item
‘message assessment’ scale (a = 0.91). We also asked
respondents about how much they trust the information in
the DSC and how much risk they think there is for a person
with heart or blood vessel disease who is taking Smoquit
(using a 4-item response scale of 1 = None, 2 = Some;
3 = A fair amount; 4 = A lot, with a ‘Don’t know’
option). The focus for this last question was on individuals
who already have heart or blood vessel disease because
they are at increased risk.
Behavioral Intentions The survey included six questions
about respondents’ intended behaviors/actions as a result of
being exposed to the DSC; that is, how likely would they
be to (1) talk with their HCP about Smoquit, (2) report any
symptoms described in the message to their HCP, (3) report
any symptoms described in the message to the FDA, (4)
look for more information about the medicine, (5) dis-
continue taking the drug. The responses to these questions
each had a 1–7 scale with end points labeled 1 = Strongly
disagree and 7 = Strongly agree. The sixth question asked
if a respondent would take Smoquit to try and stop smoking
if their doctor prescribed it; responses were on a 1–4 scale
with end points labeled 1 = Strongly disagree to
4 = Strongly agree.
2.4.2 Independent Variables
Sociodemographic, health insurance, and geographic data
were collected from respondents as part of their partici-
pation in KnowledgePanel. Participants were classified by
GfK as to whether they had Internet access or were given it
as a part of their panel participation.
Sources of Prescription Drug Information and Infor-
mation Preferences To assess what information sources
people consult about prescription drugs, we asked the fol-
lowing question: ‘‘Before taking a prescription drug, what
information source(s) would you use to learn about it?’’ A
total of 20 different response options were provided in the
Table 1 continued
Standard version of the DSC Revised version of the DSC
Health care professionals are advised to weigh the risks of Smoquit
against the benefits of its use. It is important to note that smoking is a
major risk factor for cardiovascular disease, and Smoquit is effective
in helping patients to quit smoking and abstain from it for as long as
one year
Health Care Professionals: Help your patients weigh the potential risks
and benefits of using Smoquit. Smoking is a major risk factor for
cardiovascular disease
The health benefits of quitting smoking are immediate and substantial.
Report adverse events involving Smoquit to the FDA
Smoquit can help patients to quit smoking and keep from smoking for
as long as one year. Report problems involving Smoquit to the FDA
Data Summary. Overall, there was a low incidence of major adverse
cardiovascular events occurring within 30 days of treatment
discontinuation (Smoquit 0.31 % [13/4190] vs. placebo 0.21 % [6/
2812]) in the trials included in the meta-analysis
Note: This section called ‘Data Summary’ was under a tab directed at
Health Care Professionals and was not included in the Consumer/
Patient tab
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following categories: (1) People (such as doctor or phar-
macist), (2) Traditional media (such as radio or magazine),
(3) Internet or mobile sources, and (4) Other.
To assess what kind of information people want about
prescription drugs, we asked the following question:
‘‘When you are looking for information about prescription
drugs, what kind of information do you want?’’ Response
options included ‘General use of the medicine,’ ‘Safety
information,’ ‘Possible side effects,’ ‘Dosage information
or how much to take,’ ‘What it is best used for,’ ‘I don’t
look for that information,’ and ‘Other.’
Health Literacy To evaluate health literacy level, we
used a five-item version of the Health Literacy Skills
Instrument (HLSI) [25, 26], a computer-based instrument
that measures a range of health literacy skills in the general
population (a = 0.75). This five-item version of the HLSI
focuses largely on numeracy-related skills. Respondents
use real-world stimuli such as charts, tables, maps, and
other images to answer questions about a range of health-
related topics. Each question has only one correct response
option, and scale scores are computed as the percentage of
correct responses ranging from 0 to 100.
Prescription Drug Utilization Prescription drug use was
assessed with one item: ‘‘In the past 12 months, have you
taken a prescription drug? Examples of prescription drugs
include antibiotics, antidepressants, and insulin.’’
2.5 Statistical Methods
Chi-square tests were used to determine if the two DSC
groups (Standard version versus Revised version) had
comparable demographic characteristics. Responses
between the two groups on all dependent and independent
variables were compared using Chi-square tests for cate-
gorical variables and t-tests for continuous variables.
Finally, a linear regression model was used to compare
comprehension index scores based on DSC condition while
controlling for other factors that may have an impact on
comprehension, including demographics (i.e., gender, age,
education level, race/ethnicity, income, insurance, and
geographic region), household Internet access, prescription
drug use in the past 12 months, health literacy, risk per-
ceptions, and trust in the message. We also ran an analysis
to determine the proportion of individuals who did not
accurately respond to the question about overall risk of
Smoquit and who also did not answer the question cor-
rectly about the overall risk of Smoquit. Analyses were
conducted using SAS version 9.3 survey analysis proce-
dures, and survey weights were applied to represent the
national population and adjusted for differential nonre-
sponse. The difference between weighted and unweighted




The survey completion rate was 56 %. A total of 1244
participants completed the survey (n = 620 Standard ver-
sion; n = 624 Revised version) (see Table 2); their
demographic characteristics were similar to those of the US
population. The majority of respondents were female
(51 %) and White (66 %). Respondents varied in their
level of education and mirrored the US population: 12 %
had less than a high school education, 31 % had a high
school education, 29 % had some college, and 29 % had a
college education or more. More than half of the partici-
pants (58 %) reported using a prescription drug during the
past 12 months (though recall bias may exist), and about
three quarters (76 %) of them had access to the Internet
other than what was provided by being part of the
KnowledegePanel. At some point in time, 12 % had tried
a smoking cessation drug. The mean health literacy score
was 78.4 (SD = 29.1), which is similar to the population
mean found in previous studies [25, 26]. The health literacy
index had good internal consistency, with a Cronbach’s
alpha of 0.75. No significant differences in demographic
characteristics were detected between respondents by DSC
condition.
3.2 Prescription Drug Information Seeking
When seeking information about prescription drugs, 80 %
of respondents reported that they looked for information
about possible side effects, 70 % for dosage information,
63 % about safety information, 60 % about general use of
the drug, 57 % for what the drug is best used for, 5 %
wanted some other kind of information, and 8 % would not
look for information (see Fig. 1).
The most frequently cited sources for information about
prescription drugs were doctors or HCPs (75 %), pharma-
cists (61 %), and drug package label or insert (51 %) (see
Table 3). The least frequently cited sources included social
network sites (1 %), the radio (2 %), and newspapers
(5 %). A total of 9 % of participants reported that they
would go to a government agency website for information
about prescription drugs.
3.3 Differences in Comprehension by Drug Safety
Communication Condition
The Cronbach’s alpha for the 5-item comprehension index
was 0.70, and the index scores followed a normal distri-
bution. Based on the bivariate analyses, respondents who
received the Revised version of the DSC answered more
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comprehension questions correctly (63 %) compared with
respondents who received the Standard version (52 %)
(p\ 0.001). The results of a series of chi-square tests
comparing correct answers to each individual knowledge
question indicated that respondents who received the
Revised version were significantly more likely than
respondents who received the Standard version to correctly
identify the number of people having heart-related prob-
lems after taking Smoquit if the chance was 0.31 % (63 vs
28 %), who was most likely to experience heart-related
problems (56 vs 46 %), and how common major cardio-
vascular problems are for people taking Smoquit (59 vs
48 %) (see Table 4).
Respondents recognized there was risk involved in
taking Smoquit for those with heart or blood vessel disease,
Table 2 Demographic
characteristics of respondents to
the Smoquit survey, by type of
message condition
Characteristic Original message Revised message p value
N Weighted % N Weighted %
Male 318 48 314 48 0.996
Age (years)
18–29 107 21 104 21 1.000
30–44 138 25 138 26
45–59 178 27 192 27
60? 201 26 186 26
Education
Less than high school 63 12 70 12 1.000
High school 201 31 200 31
Some college 171 29 166 29
College 189 29 184 29
Race/ethnicity
White 454 66 426 66 1.000
Black 67 12 74 12
Hispanic 66 15 87 15
Other 37 8 33 7
Income
\US$30,000 147 24 129 24 0.890
US$30,000–US$59,999 160 26 181 28
US$60,000–US$99,999 152 24 156 22
US$100,000? 165 26 154 27
Region
Northeast 111 18 109 18 1.000
Midwest 141 21 134 21
South 238 37 242 37
West 134 23 135 23
Household internet access 458 76 472 76 0.989
Medication use in past 12 months 373 58 373 59 0.620
Ever taken smoking cessation drug 62 10 85 15 0.019
Health literacy, mean (SE) 75 30 76 30 0.712
Fig. 1 Types of information consumers want about prescription
drugs (N = 1244)
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with 21 % in each condition perceiving ‘a lot’ of risk (see
electronic supplementary material 2 for additional infor-
mation about the subset of respondents reporting ‘a lot’ of
risk). Trust levels varied, with 17 % of respondents indi-
cating that they trusted the information in the DSC ‘a lot.’
No statistically significant differences existed in terms of
risk perceptions or trust between the two experimental
conditions.
Respondents who received the Revised version of the
DSC scored, on average, 10 percentage points higher on
the comprehension index than respondents who received
the Standard version after controlling for other factors
(p\ 0.001; see Table 5). Greater comprehension was
associated with being White compared with being African
American (p\ 0.014), having no health insurance
(p = 0.004), higher health literacy scores (p\ 0.001), and
greater trust in the Smoquit message (p\ 0.001). Lower
comprehension was associated with higher risk perceptions
for heart or blood vessel disease. Gender, age, education,
income, geographical region, Internet access, and medica-
tion use were not significantly associated with greater
comprehension.
3.4 Differences in Message Assessment, Risk
Perceptions, Trust, and Behavioral Intentions
by DSC Condition
The five-item message assessment scale had a Cronbach’s
alpha of 0.91, suggesting good reliability. On a scale of
1–5, the mean score was 2.9 for both DSC conditions.
Among respondents, 82 % in the Revised version group
agreed that the message was clear as compared with 73 %
in the Standard version group (p\ 0.001). However, sig-
nificantly fewer respondents who received the Revised
version (78 %) said they learned something new from it,
compared with 84 % of respondents who received the
Standard version (p = 0.015). No significant differences
were found between respondents who viewed the Standard
version compared with the Revised version with regard to
the message being informative (86 %), convincing (74 %),
or helpful (84 %).
No significant differences between groups were found
on any of the behavioral intentions measures, as shown
in Table 4. Respondents reported that they were fairly
likely to talk to their HCP about the drug after seeing the
message (mean of 5.4), report any symptoms described
in the message to their HCP (mean of 5.9), and look for
more information about the drug (mean of 5.4). Across
both groups, respondents were less likely to report
symptoms described in the DSC to the FDA (mean of
4.3) and similarly rated their likelihood of discontinuing
taking the drug after reading the DSC (mean of 4.7).
Both groups were also equally likely to rate their like-
lihood of taking Smoquit if they were trying to stop
smoking and their doctor prescribed it (mean of 2.5 out
of 4.0).
4 Discussion
This study examined how changes to a complex risk
communication message about drug safety (DSC) can have
an impact on consumers’ ability to understand and use the
information. The strategies included using plain language,
best practices in health literacy, and clear communication
principles, such as simplifying the reading level of the DSC
by using shorter sentences and words with fewer syllables;
using format and design modifications such as subheading
levels and more white space; and including numeric
information in sections geared toward lay audiences and
providing assistance with interpreting it. We found that
making these changes to the DSC significantly increased
consumers’ level of comprehension of its content, provid-
ing support for ongoing use and further exploration of these
strategies in pharmacovigilance communication research.
Comprehension among respondents exposed to the Revised
version of the DSC about a smoking cessation medication
was higher regarding potential safety issues, side effects,
and who is more likely to experience potential adverse
events.
While the changes made to the DSC had a significant
impact on consumers’ comprehension level, they had a
Table 3 Most and least
frequently cited sources for
information about prescription
drugs
Most frequently cited % (n) Least frequently cited % (n)
A doctor or healthcare professional 75 (944) Social networking sites 1 (15)
A pharmacist 61 (769) Radio 2 (26)
Medicine package label or insert 51 (663) A newspaper 5 (68)
Medical/health website 35 (437) A nonprofit organization website 6 (70)
Internet search 31 (368) Online forum or discussion group 6 (78)
A family member 22 (249) A magazine 6 (75)
A friend or coworker 14 (153) A government agency website 9 (109)
N = 1244
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Comprehension % correct % correct RR (95 % CI)











48 59 1.21 (1.07–1.37)
Who is most likely to have heart-related problems?
People taking a placebo (a sugar pill)
People taking Smoquit
People taking a placebo and those taking Smoquit are equally likely to have heart problems
There is not enough information to answer this question
Don’t know
46 56 1.21 (1.06–1.38)







59 56 0.95 (0.84–1.06)
The chance of someone having a heart-related problem if they took Smoquit was 0.31 %. How






28 63 2.22 (1.88–2.62)
What is the recommendation for people taking Smoquit?
Continue taking the medicine but cut back on the dosage
Talk to your healthcare professional if you have new or worsening symptoms of
cardiovascular or heart disease
Look for more information to see if you should continue taking the medicine
Contact the makers of Smoquit to see if you are at risk of developing cardiovascular disease
Don’t know
79 79 1.01 (0.94–1.09)





A fair amount 29 26
A lot 21 21
Don’t know 12 11
How much do you trust the information in the message?* 0.98 (0.88–1.10)
None 7 6
Some 28 30
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limited or no impact on respondents’ assessment of the
message or behavioral intentions. Participants found the
revised message to be significantly clearer; this may be due
to the reduced reading level and elimination of passive
voice, in particular. Additional changes to the format and
content of the message may be needed to have a greater
impact. While the content was the same in both versions,
respondents perceived that they learned more from the
Standard version, perhaps due to its use of more complex
terminology.
A consumer’s health literacy level was a key factor in
respondents’ level of understanding of the DSC examined
in this study. This may be because the measure of health
literacy that was used in this study, the HLSI, includes
measures of numeracy that may have been particularly
relevant because the online survey also asked participants
to answer questions containing numeric information,
including one question about the chance that someone
would have a heart-related problem if they took the med-
ication. The question involved interpreting how many
people are in a fractional percentage (0.31 %). Respon-
dents who viewed the Revised version, which explained
what that percentage means using a frequency (31 out of
10,000), were more than two times as likely to correctly
answer the question (63 vs 28 %) compared with those who
viewed the Standard version. Natural frequencies are better
understood than percentages in the context of diagnostic or
screening tests [27], and this may be the case for other risks
as well. The Standard version included the numeric infor-
mation only in the Data Summary section geared to HCPs
because of concerns at the time of its development about
the prevalence of low numeracy levels among general
health consumers. The present findings suggest that con-
sumers can understand numerical information when ade-
quate context is provided. Other research has also found
that people better understand probabilities when they are
presented with words and/or visuals that match and rein-
force the meaning of the numbers versus when numbers are
presented alone [21, 28], but fractional percentages should
be avoided [29]. Visual aids and absolute risk formats can
improve patients’ understanding of probabilistic informa-
tion, whereas ‘numbers needed to treat’ can lessen their
understanding [30]. However, graphics can be subject to
interpretation, sometimes leading to overestimation of risk
[31].
An unforeseen finding was the higher-than-expected
overall mean likelihood (mean = 4.7 on a 7-point scale) of







A fair amount 38 37
A lot 17 17
Don’t know 11 10
Message assessment % Agree/strongly agree % Agree/strongly agree RR (95 % CI)
Overall message receptivity scale, mean (SE) 2.91 (0.03) 2.91 (0.03) 0.00 (-0.08 to 0.09)
1. The message is clear 73 82 1.14 (1.06–1.22)
2. The message is informative 86 86 1.00 (0.95–1.06)
3. The message is convincing 73 75 1.03 (0.95–1.11)
4. The message is helpful 83 85 1.02 (0.96–1.08)
5. I learned something new from the message 84 78 0.92 (0.86–0.98)
Behavioral intentions Mean (SE) Mean (SE) Mean difference (95 % CI)
If you were taking Smoquit, after reading the message, how likely would you be to…?
1. Talk with your healthcare professional about Smoquit 5.37 (0.10) 5.35 (0.10) -0.02 (-0.30 to 0.26)
2. Report any symptoms described in the message to your healthcare professional 5.98 (0.09) 5.89 (0.09) -0.0.8 (-0.34 to 0.17)
3. Report any symptoms described in the message to the FDA 4.25 (0.11) 4.35 (0.11) 0.10 (-0.20 to 0.41)
4. Look for more information about the medicine 5.34 (0.10) 5.38 (0.09) 0.04 (-0.22 to 0.30)
5. Discontinue taking it 4.72 (0.10) 4.65 (0.10) -0.08 (-0.35 to 0.19)
6. Take Smoquit if trying to stop smoking 2.46 (0.04) 2.54 (0.0)4 0.08 (-0.04 to 0.20)
* Relative risk compares participants reporting a lot/a fair amount vs none/some
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they were exposed (this is in comparison to mean = 2.5 on
a 4-point scale of those who reported they would take
Smoquit if trying to stop smoking). The respondents were
hypothetical users of this fictitious medication and a
majority were non-smokers; however, this finding supports
prior research suggesting that a better understanding is
needed about the extent to which, and for what other types
of behaviors, pharmacovigilance communications might
unintentionally lead to drug nonadherence and other issues,
and how to overcome these potential consequences. For
example, further research is needed to assess if consumers
would talk to their HCP about their concerns before dis-
continuing a drug after seeing or hearing safety messages
from different sources.
Both the Standard and the Revised versions of the
communication stated that smoking is a risk factor for
cardiovascular disease and that Smoquit is used to help
people stop smoking and it increases the likelihood of
abstinence from smoking for as long as 1 year. However,
neither version directly presents other health risks of
smoking or the other benefits of quitting, or quantifies the
cardiovascular risk of smoking. Adherence to a medicine is
likely to be motivated by total risks and total benefits
associated with the medicine. Total benefits from taking
Smoquit include those associated with taking the medicine
as well as those associated with quitting smoking. How-
ever, such total analyses of risks and benefits are not
included in most methodologies to assess drug safety and
efficacy [32]. Lay audiences understand risk in multi-
faceted ways involving statistical probability, with most
viewing it as ‘‘hazard or peril [33]’’. Understanding of risk
can be influenced by ‘‘whether the risk is incurred volun-
tarily (e.g., smoking) or involuntarily (e.g., contaminants in
the environment), by how emotions color perceptions, and
by how optimistic or pessimistic the person is’’ [34, p. 86].
People also often use heuristics or shortcuts to make
judgments and base decisions such as whether to talk to a
doctor about side effects or discontinue taking a medication
[35]. Our findings provide empirical support for the rec-
ommendation that message developers should seek to
reduce cognitive burden by presenting messages with a
modest amount of information and key points that can be
easily identified within an organized and clean layout.
The randomized design and large sample size are key
strengths of the study. However, limitations of the study
are that we used a single hypothetical message for a single
drug with a population that was not actually taking the
medication; as a result, there were no behavioral outcomes
to assess. With actual patients taking the drug under study
and the ability to measure behaviors, not just intentions,
over time, the findings may have been different. The data
Table 5 Regression model of comprehension index score
Variable Comprehension
Coefficient (SE) p value
Message
Original message REF
Revised message 10.11 (1.78) \0.001
Male -0.19 (1.84) 0.918
Age
18–29 REF
30–44 -3.07 (2.94) 0.297
45–59 1.12 (2.89) 0.699
60? 0.90 (3.17) 0.776
Education
Less than high school REF
High school 2.10 (3.70) 0.571
Some college 3.55 (4.00) 0.376
College 4.84 (4.01) 0.227
Race/ethnicity
White REF
Black -7.92 (3.21) 0.014
Hispanic 1.81 (3.25) 0.579
Other 0.50 (3.84) 0.897
Income
\US$30,000 REF
US$30,000–US$59,999 0.99 (2.86) 0.730
US$60,000–US$99,999 3.33 (3.08) 0.280
US$100,000? 4.19 (3.16) 0.185
Insurance
Medicaid -0.21 (3.18) 0.948
Medicare 0.17 (2.77) 0.951
Employer REF
Other insurance -3.96 (5.89) 0.501
No insurance 9.14 (3.17) 0.004
Unknown -1.12 (3.04) 0.712
Region
Northeast -1.25 (2.91) 0.668
Midwest 2.91 (2.65) 0.273
South 1.63 (2.43) 0.503
West REF
Household Internet access 1.79 (2.66) 0.501
Medication use in past 12 months 2.99 (2.03) 0.142
Health literacy 0.40 (0.04) \0.001
Risk perceptions -6.30 (1.20) \0.001
Trust in information 4.47 (1.05) \0.001
Drug to stop smoking 1.78 (2.55) 0.487
Knowledge index – –
Comprehension model (N = 1004; R2 = 0.33)
REF reference category
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are based on self-report, respondents could have been
influenced by social desirability bias, and the absolute
change in understanding was small. These small changes
may be reliable, or they could be the result of ceiling
effects, as between 74 and 86 % endorsed how informative,
convincing, or helpful the information was for them. The
behavioral intention survey measures were developed
based on the information in the DSC but may be somewhat
generic, and the question about how ‘convincing’ the
information was could be viewed as vague, especially
given the messages did not promote any specific recom-
mended immediate-term actions. The direction of the effect
in the comprehension model cannot be determined; that is,
did risk and trust affect comprehension or did compre-
hension affect risk and trust? Taken together, these limi-
tations can have a potential impact on the internal validity
and generalizabilty of the study.
Information on US government health websites is
required to adhere to plain language principles [36].
Undertaking the process of transforming scientific infor-
mation into plain language is complicated and requires
collaboration among subject matter experts, legal experts,
and communication specialists, as well as assurance that
those with the authority to conduct the final review of the
content do not ‘undo’ the plain language implemented by
those who contributed to it before them. Some federal
agencies are implementing guidelines and processes for
ensuring that their public-facing content is understandable
[21]. Despite guidelines, developing plain language content
can be challenging and every word can matter. For
example, when revising the ‘What did they find’ section of
the Smoquit DSC, the word ‘consistently’ may only make
sense if one knows that there were various analyses con-
ducted, a fact the Revised version did not explicitly state
but was included in the Standard version. Changes in
expression, syntax, or grammar in the search for greater
simplicity and broader understanding could also potentially
influence meaning or emphasis and consequently the
outcomes.
Approval of a new drug is given only after rigorous
review; however, new research and other information that
becomes available after a drug is approved and in wide use
may reveal additional side effects, new indications for its
use, potential links of use of the drug with adverse events
(fatal and nonfatal), restrictions in populations that should
use it, or changes in prescription dose that must be com-
municated to patients, caregivers, and HCPs. Responding
to the changing science and evidence for the safety and
efficacy of approved drugs is a major challenge for public
pharmacovigilance communications because this involves
crafting relevant, comprehensible, and actionable drug
safety messages for various stakeholders. Consequently,
the FDA and similar agencies worldwide must continually
raise awareness and provide reasonable guidance to
patients, caregivers, and HCPs that informs rather than
causes unnecessary anxiety. For example, Health Canada,
the federal department responsible for maintaining and
improving the health of Canadians, is identifying, assess-
ing, and communicating safety information to Canadians.
LeBrun and colleagues [37] recently found that imple-
menting a revised Public Advisory template using plain
language principles reduced the literacy burden based on
the Suitability Assessment Test. Likewise, the FDA’s
Center for Drug Evaluation and Research is funding
research aimed at better understanding the needs of various
audiences and using this and other evidence-based infor-
mation to enhance the effectiveness of its drug-related
communications.
5 Conclusions
This study provides quantifiable evidence that incorporat-
ing clear communication and health literacy principles into
risk communication information can significantly increase
consumers’ understanding of drug safety information. This
suggests that greater effort should be made to apply such
modifications to highly technical scientific and regulatory
topics, especially when safety issues are involved. Addi-
tional research is needed using qualitative and quantitative
techniques to assess ongoing changes to drug safety mes-
sages and how communication activities may be dependent
on contextual and personal variables of the consumers,
patients, HCPs, and other stakeholders. Messages about
drug safety are clearly different than other types of risk
communications related to natural disasters or other man-
made risks and should be approached with this caveat in
mind.
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